US government wins ok to join Rapamune whistleblower suit against Pfizer
This article was originally published in Scrip
The federal government has won a US judge's approval to intervene in a whistleblower suit accusing Pfizer's Wyeth unit of illegally marketing the kidney-transplant drug Rapamune (sirolimus) for use in other, unapproved organ transplant operations, and for offering kickbacks to providers.
You may also be interested in...
Corindus Vascular Robotics Inc. expects its CorPath GRX robotic intervention system will eventually be part of a widespread system of "telerobotic" intervention sites operated by specialists located far away. See what Tejas Patel, an interventional cardiologist at the Apex Heart Institute in Ahmedabad, India, said about it here.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.